Losartan

Generic Name: Losartan

Brand Names: Hyzaar, Cozaar

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃ClN_₆O

CAS Number: 114798-26-4

Unique Ingredient Identifier: JMS50MPO89

Background: Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...

Indication: Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...

Associated Conditions: Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Associated Therapies: -

Clinical Trials

Losartan and Emotion Processing

Not Applicable

Conditions: Healthy

Interventions: Drug: Placebo Oral Tablet
Drug: Losartan

First Posted Date: 2018-01-11

Last Posted Date: 2018-06-06

Lead Sponsor: University of Electronic Science and Technology of China

Target Recruit Count: 70

Registration Number: NCT03396523

Locations: 🇨🇳
University of Electronic Science and Technology of China, Chengdu, Sichuan, China

AT1R Blockade and Periodic Breathing During Sleep in Hypoxia

Phase 4

Completed

Conditions: Sleep Disordered Breathing
Hypoxia
Respiration; Sleep Disorder
Chemoreceptor Apnea

Interventions: Other: Hyperoxic Hypercapnic Ventilatory Response Test
Other: Hypoxic Hypercapnic Ventilatory Response Test
Other: Repeated Hypoxic Apneas
Other: Hypoxic Sleep Study
Drug: Placebo
Drug: Losartan

First Posted Date: 2017-11-08

Last Posted Date: 2020-09-04

Lead Sponsor: University of British Columbia

Target Recruit Count: 14

Registration Number: NCT03335904

Locations: 🇨🇦
University of British Columbia, Kelowna, British Columbia, Canada

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

Phase 2

Active, not recruiting

Conditions: Sedentary Lifestyle
Aging
Hypertension

Interventions: Behavioral: Aerobic exercise
Drug: Perindopril
Drug: Losartan
Drug: HCTZ

First Posted Date: 2017-09-28

Last Posted Date: 2024-05-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 213

Registration Number: NCT03295734

Locations: 🇺🇸
UAB Center for Exercise Medicine, Birmingham, Alabama, United States
🇺🇸
Translational Research Institute, Orlando, Florida, United States

A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension

Phase 4

Completed

Conditions: Hypertension
Pharmacogenetics

Interventions: Drug: Placebo
Drug: Amlodipine
Drug: Losartan
Drug: Bisoprolol
Drug: Hydrochlorothiazide

First Posted Date: 2017-09-08

Last Posted Date: 2017-09-11

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 233

Registration Number: NCT03276598

Locations: 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland

Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: Losartan
Drug: Rostafuroxin

First Posted Date: 2017-07-14

Last Posted Date: 2023-02-21

Lead Sponsor: Windtree Therapeutics

Target Recruit Count: 240

Registration Number: NCT03217825

Locations: 🇨🇳
Cvie Therapeutics Limited, Taipei, Taiwan

Losartan and Inflammation in Cystic Fibrosis

Phase 2

Terminated

Conditions: Cystic Fibrosis

Interventions: Drug: placebo
Drug: Losartan

First Posted Date: 2017-07-02

Last Posted Date: 2020-11-27

Lead Sponsor: University of Miami

Target Recruit Count: 7

Registration Number: NCT03206788

Locations: 🇺🇸
University of Kansas, Kansas City, Kansas, United States
🇺🇸
University of Miami, Miller School of Medicine, Miami, Florida, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 1 locations

Matão Controlling Hypertension (MatCH Study): Rationale and Design

Early Phase 1

Conditions: Hypertension
Blood Pressure

Interventions: Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,
Drug: Atenolol
Drug: Losartan potassium 50mg
Drug: Clonidine

First Posted Date: 2017-05-10

Last Posted Date: 2017-11-21

Lead Sponsor: Centro Neurológico de Pesquisa e Reabiitação, Brazil

Target Recruit Count: 15000

Registration Number: NCT03147092

Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function

Phase 3

Terminated

Conditions: Cerebral Small Vessel Diseases

Interventions: Drug: Amlodipine
Drug: Losartan
Drug: Atenolol

First Posted Date: 2017-03-17

Last Posted Date: 2023-03-09

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 101

Registration Number: NCT03082014

Locations: 🇩🇪
Insitute for Stroke and Dementia Research, Munich, Germany
🇳🇱
Maastricht University Medical Center, Maastricht, Netherlands
🇬🇧
Centre for Clinical Brain Sciences, Edinburgh, Scotland, United Kingdom

and more 2 locations

An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)

Phase 2

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Losartan Potassium

First Posted Date: 2017-01-24

Last Posted Date: 2020-09-09

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 15

Registration Number: NCT03029091

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of California, San Diego, La Jolla, California, United States

Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy

Phase 4

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: Pentoxifylline
Drug: Losartan

First Posted Date: 2016-12-30

Last Posted Date: 2016-12-30

Lead Sponsor: Tehran University of Medical Sciences

Target Recruit Count: 59

Registration Number: NCT03006952

Locations: 🇮🇷
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy